Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06075771 · ClinicalTrials.gov registry record · Phase 4
Dopaminergic Therapy for Anhedonia - 2
A Phase 4 study of Depression and Anhedonia, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT06075771 is a Phase 4 study of Depression and Anhedonia that is actively recruiting participants, run by Emory University. The registered enrollment target is 70 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06075771, a Phase 4 study of Depression and Anhedonia, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedonia will be randomized to receive L-DOPA or matched placebo over 8 weeks. Participants will complete lab tests, medical and psychiatric assessments, motivation and motor tasks, and MRI scans as part of the study. The total length of participation is approximately 10 to 12 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Carbidopa Levodopa
Study Locations (1)
Georgia
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-11-21 |
| Est. Completion | 2027-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06075771
The ClinicalTrials.gov registry entry for NCT06075771 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (91% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06075771 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06075771 about?
NCT06075771 is a clinical study titled "Dopaminergic Therapy for Anhedonia - 2". The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedo...
What is the current status of trial NCT06075771?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2023-11-21. Estimated completion is 2027-01.
What conditions does trial NCT06075771 study?
This clinical trial studies the following conditions: Depression, Anhedonia.
What interventions are being tested in trial NCT06075771?
The interventions under investigation include: Placebo (DRUG), Carbidopa Levodopa (DRUG).
Who is sponsoring clinical trial NCT06075771?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06075771 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
-
Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.